An intensive blood pressure-lowering intervention delivered by non-physician health care providers reduced dementia incidence by 15% over seven years compared with usual care, according to trial results presented at ESC Congress 2026. At the same time, clinical trials demonstrated that subcutaneous plozasiran injections cut triglyceride levels by roughly 80% and lowered acute pancreatitis events in patients with severe hypertriglyceridemia.
Intensive Blood Pressure Control Cuts Dementia Risk by 15%
According to data from the China Rural Hypertension Control Program (CHRCP) trial presented at ESC Congress 2026, participants who received an intensive blood pressure-lowering intervention experienced a 15% reduction in dementia incidence over seven years compared to those receiving usual care. Furthermore, the analysis revealed a 13% lower risk of cognitive impairment and no dementia.
“In this large community-based trial, a scalable intervention delivered by non-physician health care providers not only resulted in substantial reductions in BP but also reduced the risk of dementia,” said Yingxian Sun, MD, from The First Affiliated Hospital of China Medical University, Shenyang, China. Sun noted that these results support the long-term sustainability of integrating structured blood pressure management into routine primary care for population-level dementia prevention. Prior findings from the CHRCP trial already established that community-delivered intensive interventions successfully lower blood pressure and reduce cardiovascular events.
Did you know?
Plozasiran Lowers Triglycerides by 80% in Severe Hypertriglyceridemia
Severe hypertriglyceridemia carries a dangerous risk of acute pancreatitis, yet standard therapeutic options often fall short. Data from the international SHASTA-3 and SHASTA-4 trials, conducted across 24 countries, show that administering plozasiran via subcutaneous injection every three months reduced triglyceride levels by roughly 80% after one year compared to a placebo. Investigators also observed a significant reduction in acute pancreatitis events among patients receiving plozasiran vs. placebo.
“Results from the SHASTA-3 and SHASTA-4 studies build on the positive results from other plozasiran trials across various patient populations, including those with the most severe form of hypertriglyceridemia, familial chylomicronemia syndrome,” said Gerald Watts, MD, from Australia. Watts emphasized that currently available treatments are frequently insufficient to manage severe lipid abnormalities, positioning plozasiran as a promising intervention across the clinical spectrum of severe hypertriglyceridemia.
Comparing Cardiovascular and Cardiometabolic Trial Outcomes
While the CHRCP trial evaluated a blood pressure strategy delivered by community health providers over seven years, the SHASTA-3 and SHASTA-4 trials tested plozasiran administered quarterly over one year.
Frequently Asked Questions
How much did intensive blood pressure management reduce dementia risk?
According to ESC Congress 2026 data from the CHRCP trial, intensive blood pressure-lowering reduced dementia incidence by 15% and lowered the risk of cognitive impairment and no dementia by 13% over seven years.
How is plozasiran administered for severe hypertriglyceridemia?
Plozasiran is delivered via subcutaneous injection every three months, as demonstrated in the SHASTA-3 and SHASTA-4 trials conducted across 24 countries.
What effect does plozasiran have on triglycerides and pancreatitis?
Trial investigators reported that plozasiran reduced triglyceride levels by roughly 80% after one year and significantly reduced acute pancreatitis events compared to placebo.
Explore More: Stay up to date with the latest cardiology breakthroughs by visiting ACC’s ESC Congress 2026 coverage page for in-depth science and key takeaways shaping modern cardiovascular care.
Worth a look